A Explore Study of Bevacizumab Combined With Conventional Therapy in Glioblastoma

Inclusion Criteria: * Histologically proven newly diagnosis of glioblastoma (WHO grade IV) * The tumor must have a supratentorial component * The patient must have recovered from the effects of surgery, postoperative infection, and other complications before initial chemoradiation treatment * Documentation of steroid doses within 14 days prior to initial chemoradiation treatment * Karnofsky performance status ≥ 70; * Age ≥ 18 * Adequate renal function,hepatic function * Systolic blood pressure ≤ 160 mg Hg or diastolic pressure ≤ 90 mg Hg within 14 days prior to initial chemoradiation treatment * Patient must provide study specific informed consent prior to study entry * Women of childbearing potential and male participants must practice adequate contraception. * For females of child-bearing potential, negative serum pregnancy test within 14 days prior to initial chemoradiation treatment Exclusion Criteria: * Cancer-Related Exclusion Criteria * Prior invasive malignancy (except for non-melanomatous skin cancer) unless disease free for ≥3 years * Recurrent or multifocal malignant gliomas * Metastases detected below the tentorium or beyond the cranial vault * Prior chemotherapy or radiosensitizers for cancers of the head and neck region; note that prior chemotherapy for a different cancer is allowable, except prior temozolomide or bevacizumab. Prior use of Gliadel wafers or any other intratumoral or intracavitary treatment are not permitted. * Prior radiotherapy to the head or neck (except for T1 glottic cancer), resulting in overlap of radiation fields * Haematologic, Biochemical, Organ Function and other general exclusion criteria * Unstable angina and/or congestive heart failure within the last 6 months * Transmural myocardial infarction within the last 6 months * Evidence of recent myocardial infarction or ischemia by the findings of S-T elevations of ≥ 2mm using the analysis of an EKG performed within 14 days of initial chemoradiation treatment * New York Heart Association grade II or greater congestive heart failure requiring hospitalization within 12 months prior to initial chemoradiation treatment * History of stroke, cerebral vascular accident (CVA) or transient ischemic attack within 6 months * Serious and inadequately controlled cardiac arrhythmia * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of initial chemoradiation treatment * Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however,that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol * Inability to undergo MRI (e.g., due to safety reasons,such as presence of a pacemaker) or PET * Contradiction to Bevacizumab treatment